Aortic Iron Overload with Oxidative Stress and Inflammation in Human and Murine Abdominal Aortic Aneurysm

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 6, 2015, Pages 1507-1514

  Sawada, Hisashi ^a   Hao, Hiroyuki ^a   Naito, Yoshiro ^a   Oboshi, Makiko ^a   Hirotani, Shinichi ^a   Mitsuno, Masataka ^a   Miyamoto, Yuji ^a   Hirota, Seiichi ^a   Masuyama, Tohru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

aneurysm; inflammation; iron; oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANGIOTENSIN II; APOLIPOPROTEIN E; CD68 ANTIGEN; CD71 ANTIGEN; IRON; MATRIX METALLOPROTEINASE; STRESS ACTIVATED PROTEIN KINASE; 8-OXO-7-HYDRODEOXYGUANOSINE; CD68 ANTIGEN, HUMAN; DEOXYGUANOSINE; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; TFRC PROTEIN, MOUSE; TRANSFERRIN RECEPTOR;

ABDOMINAL AORTA; ABDOMINAL AORTA ANEURYSM; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA WALL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; IRON INTAKE; IRON OVERLOAD; IRON RESTRICTION; IRON TRANSPORT; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANALOGS AND DERIVATIVES; ANIMAL; AORTA; DIET THERAPY; FIBROSIS; KNOCKOUT MOUSE; METABOLISM; PHOSPHORYLATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; AORTA; AORTIC ANEURYSM, ABDOMINAL; DEOXYGUANOSINE; FEMALE; FIBROSIS; HUMANS; INFLAMMATION; IRON OVERLOAD; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MACROPHAGES; MALE; MATRIX METALLOPROTEINASES; MICE, KNOCKOUT; OXIDATIVE STRESS; PHOSPHORYLATION; RECEPTORS, TRANSFERRIN;

EID: 84933045429     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.305586     Document Type: Article

References (40)

1. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol. 2011;8:92-102. doi: 10.1038/nrcardio.2010.180.
2. Wassef M, Baxter BT, Chisholm RL, Dalman RL, Fillinger MF, Heinecke J, Humphrey JD, Kuivaniemi H, Parks WC, Pearce WH, Platsoucas CD, Sukhova GK, Thompson RW, Tilson MD, Zarins CK. Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. J Vasc Surg. 2001;34:730-738. doi: 10.1067/mva.2001.116966.
3. Hellenthal FA, Buurman WA, Wodzig WK, Schurink GW. Biomarkers of AAA progression. Part 1: extracellular matrix degeneration. Nat Rev Cardiol. 2009;6:464-474. doi: 10.1038/nrcardio.2009.80.
4. Hellenthal FA, Buurman WA, Wodzig WK, Schurink GW. Biomarkers of abdominal aortic aneurysm progression. Part 2: inflammation. Nat Rev Cardiol. 2009;6:543-552. doi: 10.1038/nrcardio.2009.102.
5. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006;121:144-158. doi: 10.1016/j.clim.2006.06.010.
6. Naito Y, Fujii A, Sawada H, Hirotani S, Iwasaku T, Eguchi A, Ohyanagi M, Tsujino T, Masuyama T. Effect of iron restriction on renal damage and mineralocorticoid receptor signaling in a rat model of chronic kidney disease. J Hypertens. 2012;30:2192-2201. doi: 10.1097/HJH.0b013e3283581a64.
7. Lee TS, Shiao MS, Pan CC, Chau LY. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation. 1999;99:1222-1229.
8. Martinez-Pinna R, Lindholt JS, Madrigal-Matute J, et al. From tissue iron retention to low systemic haemoglobin levels, new pathophysiological biomarkers of human abdominal aortic aneurysm. Thromb Haemost. 2014;112:87-95. doi: 10.1160/TH13-08-0721.
9. Naito Y, Hirotani S, Sawada H, Akahori H, Tsujino T, Masuyama T. Dietary iron restriction prevents hypertensive cardiovascular remodeling in Dahl salt-sensitive rats. Hypertension. 2011;57:497-504. doi: 10.1161/HYPERTENSIONAHA.110.159681.
10. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004;24:429-434. doi: 10.1161/01. ATV.0000118013.72016.e.a.
11. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26:987-994. doi: 10.1161/01.ATV.0000214999.12921.4f.
12. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004;117:285-297.
13. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142:24-38. doi: 10.1016/j.cell.2010.06.028.
14. Nathan C. Points of control in inflammation. Nature. 2002;420:846-852. doi: 10.1038/nature01320.
15. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation. 2003;108:2034-2040. doi: 10.1161/01.CIR.0000093661.90582.c4.
16. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381-1478. doi: 10.1152/physrev.00047.2003.
17. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
18. Miller FJ Jr, Sharp WJ, Fang X, Oberley LW, Oberley TD, Weintraub NL. Oxidative stress in human abdominal aortic aneurysms: a potential mediator of aneurysmal remodeling. Arterioscler Thromb Vasc Biol. 2002;22:560-565.
19. Gavrila D, Li WG, McCormick ML, Thomas M, Daugherty A, Cassis LA, Miller FJ Jr, Oberley LW, Dellsperger KC, Weintraub NL. Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:1671-1677. doi: 10.1161/01.ATV.0000172631.50972.0f.
20. Kaneko H, Anzai T, Morisawa M, et al. Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization. Atherosclerosis. 2011;217:350-357. doi: 10.1016/j.atherosclerosis.2011.03.042.
21. Parastatidis I, Weiss D, Joseph G, Taylor WR. Overexpression of catalase in vascular smooth muscle cells prevents the formation of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2013;33:2389-2396. doi: 10.1161/ATVBAHA.113.302175.
22. Naito Y, Fujii A, Sawada H, Hirotani S, Iwasaku T, Okuhara Y, Eguchi A, Ohyanagi M, Tsujino T, Masuyama T. Dietary iron restriction prevents further deterioration of renal damage in a chronic kidney disease rat model. J Hypertens. 2013;31:1203-1213. doi: 10.1097/HJH.0b013e328360381d.
23. Naito Y, Sawada H, Oboshi M, Fujii A, Hirotani S, Iwasaku T, Okuhara Y, Eguchi A, Morisawa D, Ohyanagi M, Tsujino T, Masuyama T. Increased renal iron accumulation in hypertensive nephropathy of salt-loaded hypertensive rats. PLoS One. 2013;8:e75906. doi: 10.1371/journal. pone.0075906.
24. Davis V, Persidskaia R, Baca-Regen L, Itoh Y, Nagase H, Persidsky Y, Ghorpade A, Baxter BT. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 1998;18:1625-1633.
25. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, Mecham RP, Welgus HG, Parks WC. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest. 1995;96:318-326. doi: 10.1172/JCI118037.
26. Scaccabarozzi A, Arosio P, Weiss G, Valenti L, Dongiovanni P, Fracanzani AL, Mattioli M, Levi S, Fiorelli G, Fargion S. Relationship between TNFalpha and iron metabolism in differentiating human monocytic THP-1 cells. Br J Haematol. 2000;110:978-984.
27. Nairz M, Schroll A, Demetz E, Tancevski I, Theurl I, Weiss G. 'Ride on the ferrous wheel'-the cycle of iron in macrophages in health and disease. Immunobiology. 2015;220:280-294. doi: 10.1016/j.imbio.2014.09.010.
28. Saraff K, Babamusta F, Cassis LA, Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1621-1626. doi: 10.1161/01.ATV.0000085631.76095.64.
29. Michel JB, Martin-Ventura JL, Egido J, Sakalihasan N, Treska V, Lindholt J, Allaire E, Thorsteinsdottir U, Cockerill G, Swedenborg J; FAD EU consortium. Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc Res. 2011;90:18-27. doi: 10.1093/cvr/cvq337.
30. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, Hoshii Y, Tanaka N, Ricci R, Ishihara T, Esato K, Hamano K, Matsuzaki M. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med. 2005;11:1330-1338. doi: 10.1038/nm1335.
31. Tsai SH, Huang PH, Peng YJ, Chang WC, Tsai HY, Leu HB, Chen JW, Lin SJ. Zoledronate attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of Rho/ROCK-dependent JNK and NF-?B pathway. Cardiovasc Res. 2013;100:501-510. doi: 10.1093/cvr/cvt230.
32. Torsney E, Pirianov G, Charolidi N, Shoreim A, Gaze D, Petrova S, Laing K, Meisinger T, Xiong W, Baxter BT, Cockerill GW. Elevation of plasma high-density lipoproteins inhibits development of experimental abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2012;32:2678-2686. doi: 10.1161/ATVBAHA.112.00009.
33. Kintscher U, Wakino S, Kim S, Fleck E, Hsueh WA, Law RE. Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension. 2001;37(2 Pt 2):587-593.
34. Ishida M, Ishida T, Thomas SM, Berk BC. Activation of extracellular signal-regulated kinases (ERK1/2) by angiotensin II is dependent on c-Src in vascular smooth muscle cells. Circ Res. 1998;82:7-12.
35. Murasawa S, Mori Y, Nozawa Y, Masaki H, Maruyama K, Tsutsumi Y, Moriguchi Y, Shibasaki Y, Tanaka Y, Iwasaka T, Inada M, Matsubara H. Role of calcium-sensitive tyrosine kinase Pyk2/CAKbeta/RAFTK in angiotensin II induced Ras/ERK signaling. Hypertension. 1998;32:668-675.
36. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA. 2007;297:603-610. doi: 10.1001/jama.297.6.603.
37. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst. 2008;100:996-1002. doi: 10.1093/jnci/djn209.
38. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am Heart J. 2011;162:949-957.e1. doi: 10.1016/j.ahj.2011.08.013.
39. Iwasa M, Kaito M, Ikoma J, Kobayashi Y, Tanaka Y, Higuchi K, Takeuchi K, Iwata K, Watanabe S, Adachi Y. Dietary iron restriction improves aminotransferase levels in chronic hepatitis C patients. Hepatogastroenterology. 2002;49:529-531.
40. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341:1986-1995. doi: 10.1056/NEJM199912233412607.